Breathe Well Live Well
|
Five Prime strikes deal with GSK for asthma drug
San Francisco Business Times The collaboration will give GlaxoSmithKline exclusive access to therapeutic drugs developed by Five Prime for refractory asthma and chronic obstructive pulmonary disease. The deal will allow Five Prime to receive up to $30 million over the next four … Five Prime Therapeutics Announces Second Strategic Alliance With GlaxoSmithKline |
View full post on asthma – Google News
 Citybizlist |
Targacept: Drug missed goal due to analysis error
BusinessWeek Drug developer Targacept Inc. said Tuesday that further analysis showed an experimental asthma treatment failed one one of its goals in a clinical trial, contrary to what the company previously reported. Targacept shares lost 59 cents, or 12.2 percent, … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept reports error in asthma study Targacept loses big shareholder, finds error in previous study |
View full post on asthma – Google News
|
Actelion ends development of asthma and SAR drug
Pharma Times Actelion has suffered a pipeline setback with the failure of its asthma and seasonal allergic rhinitis drug setipiprant in a mid-stage and a late-stage trial. The Swiss biotech says that it will "re-direct its development efforts in the … |
View full post on asthma – Google News
|
Cure for common cold announced by Australian drug maker
Catholic Online The compound was tested in 300 asthmatic patients infected with the cold-causing human rhinovirus. The trial proved that cold symptoms eased quickly and the duration of the infection was shortened considerably. LOS ANGELES, CA (Catholic Online) – The … New Drug May Cure Common Cold Drug Breakthrough for Colds Firm Claims Drug to Cure Common Cold |
View full post on asthma – Google News
 89.3 KPCC |
Drug cost-sharing results in reduced use of necessary medications in children …
Pediatric SuperSite Health insurers' cost-sharing policies may be to blame for a dip in necessary medication use among families that have a child with asthma, according to a recent study. Pinar Karaca-Mandic, PhD, and colleagues of the Division of Health Policy and … Are Parents Price-Sensitive About Their Children's Medication? Gasping for dollars: Insurance companies take your breath away Study: Higher insurance co-pays may have serious unintended consequences for … |
View full post on asthma – Google News
|
Mixed Data for Glaxo & THRX Drug
Zacks.com GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced top-line data from phase III studies conducted with their pipeline candidate, Relovair, for chronic obstructive pulmonary disease (COPD) and asthma. Relovair is a combination of … Breathe Easy: Program Complete, Data Solid |
View full post on asthma – Google News
|
Targacept slips on mixed results from drug studies
BusinessWeek Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Targacept discontinues two clinical trials, reports success with a third Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials |
View full post on asthma – Google News
|
High Copays Cut Asthma Drug Use in Older Kids
MedPage Today Explain that a retrospective study found increased cost-sharing for asthma prescriptions was associated with decreased use of medication and a higher rate of hospitalization in children over the age of 5 with asthma. Note that emergency department … Asthmatic children get fewer meds when cost hits parents more High Out-of-Pocket Costs for Kids' Asthma Drugs Could Pose Dangers Greater Medication Cost-Sharing Associated With Reduced Use of Asthma … |
View full post on asthma – Google News
|
Targacept says drug candidate worked as an asthma treatment, but fails as …
Greenfield Daily Reporter AP WINSTON-SALEM, NC — Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials Targacept reports mixed data from two trials |
View full post on asthma – Google News
|
Targacept says drug candidate worked as an asthma treatment, but fails as …
The Republic AP WINSTON-SALEM, NC — Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials Targacept reports mixed data from two trials |
View full post on asthma – Google News